In the phase 3 BRUIN CLL-314 trial (NCT05254743), pirtobrutinib (Jaypirca) achieved noninferior overall response rates (ORR) compared with ibrutinib (Imbruvica) in patients with previously untreated or relapsed/refractory chronic lymphocytic…
Pirtobrutinib Matches Ibrutinib in ORR, Shows Potential PFS Edge in BTK Inhibitor–Naive CLL/SLL
